Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trillium Therapeutics, a wholly owned subsidiary of Stem Cell Therapeutics, has completed dosing of patients with interstitial cystitis/bladder pain syndrome (IC/BPS) in first phase study of TTI-1612.
Subscribe to our email newsletter
The safety and tolerability profile of single ascending doses of TTI-1612 will be assessed in the study.
Stem Cell Therapeutics chief scientific officer Dr. Bob Uger said, "We are encouraged by our clinical experience to date with this drug, and believe we are setting the groundwork for a partner to move this program forward into Phase II testing."
The study, which enrolled 28 patients, also evaluated pharmacokinetics and changes in disease symptoms.
Preliminary results indicate that the drug was well tolerated and exhibits a favourable pharmacokinetic profile.
The locally-delivered recombinant growth factor TTI-1612 is being developed to correct the dysfunction and restore the bladder epithelium to a normal, healthy state.